Result of Meeting - Part 2

AstraZeneca PLC 12 December 2000 PART 2 AstraZeneca R&D Pipeline: NCEs Cardiovascular Compound Mechanism Indication Phase Estimated Filing MAA NDA ZD4522 Statin Hyperlipidemia DFL 2Q 2Q 2001 2001 Melagatran Thrombin inhibitor Prevention of DFL 2H 2H (s.c) VTE 2002* 2002* H376/95 Thrombin inhibitor Prevention of DFL 2H 2H (oral) VTE 2002* 2002* H376/95 Thrombin inhibitor Prevention of DFL 2Q 2Q (oral) stroke in AF 2003 2003 H376/95 Thrombin inhibitor Treatment of DFL 2003* 2003* (oral) VTE H376/95 Thrombin inhibitor Post MI CT >2003 >2003 (oral) AR-C69931 P2T antagonist (iv) Arterial CT >2003 >2003 thrombosis AZD 6140 (AR- P2T antagonist Arterial CT >2003 >2003 C126532) (oral) thrombosis AZ 242 (AR- PPAR agonist Diabetes CT 2003 2003 H039242) /Insulin resistance AR-H049020 PPAR agonist Diabetes CT >2003 >2003 /Insulin resistance ZD4927 Factor Xa inhibitor Thrombosis CT >2003 >2003 AR-H050642 Atrial selective Atrial CT >2003 >2003 anti-arrhythmic fibrillation (oral, incl. H345/52 for POC) Nortran Atrial selective Atrial PC inlicense anti-arrhythmic fibrillation (oral) * subject to confirmation Gastrointestinal AR-H047108 Reversible acid pump Acid related CT >2003 >2003 inhibitor GI disease Reflux Inhibitor of Gastroesopha CT >2003 >2003 inhibitor transient lower -geal reflux esophageal sphincter disease relaxations (TLESR) (GERD) Rofleponide Oral steroid with Inflammatory CT >2003 >2003 topical action bowel disease H.pylori Nasal/oral Vaccine H.pylori PC vaccine eradication H.pylori NCE Oral treatment H.pylori PC project eradication CNS NXY-059 Free radical Stroke CT 2003 2003 trapping agent NAD299 5HT1A antagonist Anxiety CT >2003 >2003 /Depression AR-A2 5HT1b antagonist Anxiety PC /Depression Remacemide NMDA antagonist Parkinson's CT >2003 >2003 Disease DFL 3Q 3Q Huntington's 2001 2001 chorea AR-R15896 NMDA antagonist CNS PC disorders AZD0947 K+ channel opener overactive CT >2003 >2003 bladder AZD5106 NK-2 antagonist overactive PC bladder Oncology Compound Mechanism Indication Phase Estimated Filing MAA NDA Faslodex Anti-oestrogen 2nd line DFL 1Q 1Q Advanced 2001 2001 breast cancer Faslodex Anti-oestrogen 1st line DFL 1Q 1Q Advanced 2002 2002 breast cancer Iressa Signal transduction Solid tumours DFL 4Q 4Q (ZD1839) inhibitor (Epidermal 2001 2001 growth factor receptor tyrosine kinase inhibitor) ZD0473 3rd generation Solid tumours CT 2Q 2Q platin (iv) 2003 2003 ZD0473 3rd generation Solid tumours PC platin (oral) ZD9331 Thymidilate synthase Solid tumours CT 2Q 2Q inhibitor (iv) 2003 2003 ZD9331 Thymidilate synthase Solid tumours CT >2003 >2003 inhibitor (oral) ZD6126 Vascular targeting Solid tumours PC agent AZD6474 Anti-angiogenic Solid tumours CT >2003 >2003 (Vascular endothelial cell growth factor receptor tyrosine kinase inhibitor) AZD3409 Farnesyl-transferase Solid tumours CT >2003 >2003 inhibitor ( FAR ) Respiratory and Inflammation Symbicort Inhaled Asthma DFL Launched TBD Turbuhaler steroid/long- acting b2 agonist Symbicort Inhaled COPD DFL 3Q 2002 TBD Turbuhaler steroid/long- actin b2 agonist Symbicort Inhaled Asthma/COPD DFL 3Q 2002 >2003 pMDI steroid/long- acting b2 agonist Viozan Dual dopamine/b2 COPD DFL 4Q 2001 4Q agonist 2001 Rofleponide Intranasal steroid Rhinitis CT 2003 2003 palmitate AR-C89855 Dual dopamine/b2 COPD CT >2003 >2003 agonist ZD4407 5-lipoxygenase COPD CT >2003 >2003 inhibitor ZD2315 Immuno modulator Rheumatoid CT >2003 >2003 Arthritis CCR2b Immuno modulator Rheumatoid CT >2003 >2003 Arthritis Pain Control LEF Peripheral m- Acute CT 4Q 2002 4Q agonist (iv) /chronic pain 2002 LTA Na channel blocker Analgesia CT 2003 2003 NO-naproxen Nitric oxide NSAID Acute CT >2003 >2003 derivative /chronic pain NO-NSAID II Nitric oxide NSAID Acute PC derivative /chronic pain Delta agonist Delta opioid Acute PC /chronic pain Oral glycine NMDA Antagonist Neuropathic PC pain Infection AZD2563 Oxazolidinone Gram positive CT >2003 >2003 antibiotic infections, including multi- resistant strains AstraZeneca R&D Pipeline: Line Extensions Cardiovascular Compound Mechanism Indication Phase Estimated Filing MAA NDA Seloken ZOK b-blocker CHF Appro- Appro- /Toprol-XL ved ved Atacand Angiotensin II Hypertension DFL 3Q 3Q antagonist outcomes 2002 2002 (SCOPE study) CHF outcomes DFL 2Q 2Q (CHARM study) 2003 2003 Diabetic DFL >2003 >2003 retinopathy Atacand Angiotensin II Hypertension Appro- Appro- Plus antagonist ved ved diuretic NB. Paediatric programmes ongoing/planned : Zestril, Atacand, Seloken/Toprol, Plendil Gastrointestinal Nexium Proton pump Multiple inhibitor indications (e.g. NSAID and Dyspepsia) Losec Proton pump inhibitor Entocort Oral steroid with Inflammatory Launched 4Q topical action bowel disease 2000 CNS Seroquel D2/5HT2 Granules DFL 2Q 2Q antagonist 2001 2001 Seroquel D2/5HT2 Sustained DFL 3Q 3Q antagonist release 2002 2002 Seroquel D2/5HT2 Mania DFL 2Q 3Q antagonist 2003 2002 Zomig 5-HT1B/1D Rapimelt Launched Filed receptor agonist Zomig 5-HT1B/1D Adolescents DFL 2Q 2Q receptor agonist 2002 2002 Zomig 5-HT1B/1D Nasal spray DFL Filed 1Q receptor agonist 2001 Oncology Arimidex Aromatase Adjuvant DFL 1Q 2002 1Q inhibitor Breast Cancer 2002 Casodex Anti-androgen Early Prostate DFL 1Q 1Q Cancer 2001* 2001* Tomudex Thymidylate Other tumours CT/DFL 4Q 2001 ----- synthase inhibitor Zoladex LHRH agonist Premenopausal DFL Filed 1Q Adjuvant 2001 Breast Cancer * subject to confirmation Respiratory Accolate Leukotriene Paediatrics DFL Filed Launched antagonist Asthma Pulmicort Inhaled steroid Asthma DFL Launched Launched Respules Oxis Long-acting b2 COPD DFL 4Q >2003 agonist 2001 Oxis Long-acting b2 Asthma DFL Launched 2Q agonist 2003 Oxis Long-acting b2 Paediatrics DFL 2Q 2Q agonist Asthma 2001 2003 T3 Dry powder Asthma CT TBD TBD inhaler, non- reservoir Pain Control Compound Mechanism Indication Phase Estimated Filing MAA NDA Naropin Sodium channel Spinal DFL 4Q 4Q blocker anaesthesia 2001 2001 Intra- DFL 4Q 4Q articular 2001 2001 admin. Paediatrics DFL 4Q 4Q 2002 2002 Dental Gel Topical Dental DFL 1Q 1Q anaesthesia anaesthesia 2002 2002 Infection Merrem Carbapenem Hospital & DFL 4Q antibiotic community 2000 acquired pneumonia Merrem Carbapenem Use in DFL 2Q antibiotic Neutropenics 2003 Merrem Carbapenem Cystic DFL 4Q antibiotic Fibrosis 2001 Merrem Carbapenem Skin and soft DFL 2Q antibiotic tissue 2002 infections Merrem Carbapenem Abdominal DFL 2Q antibiotic infections 2002 AstraZeneca R&D Pipeline: Discontinued Compounds Cardiovascular Compound Mechanism H409/22 NPY antagonist CNS Zendra GABAA enhancer Infection ME609 Antiviral (Medivir joint development) Comments AstraZeneca, Faslodex, Iressa, Symbicort, Turbuhaler, Viozan, Seloken ZOK, Toprol-XL, Atacand, Nexium, Losec, Entocort, Seroquel, Zomig, Arimidex, Casodex, Tomudex, Zoladex, Accolate, Pulmicort, Pulmicort Respules, Oxis, Naropin, Merrem and Zendra are trade marks of the AstraZeneca group. As disclosure of compound information is balanced by the business need to maintain competitive advantage, some compound information has not been disclosed at this time. AstraZeneca is using a new terminology for the stage of development; PC - pre-clinical, prior to CD nomination CT - concept testing, from CD nomination, through to phase I and phase II completion DFL - development for launch, phase IIIa and phase IIIb activities conducted prior to filing Other abbreviations; TBD - to be decided CD - Candidate Drug MAA - Marketing Authorisation Application (Europe) NDA - New Drug Application (USA) 12 December 2000

Companies

AstraZeneca (AZN)
UK 100
FTSE quotes by TradingView

Latest directors dealings

All directors dealings today